The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges

Eun Jin Yun, U. Ging Lo, Jer Tsong Hsieh

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Prostate cancer (PCa) is the most common cause of malignancy in males and the second leading cause of cancer mortality in United States. Current treatments for PCa include surgery, radiotherapy, and androgen-deprivation therapy. Eventually, PCa relapses to an advanced castration-resistant PCa (CRPC) that becomes a systematic disease and incurable. Therefore, identifying cellular components and molecular mechanisms that drive aggressive PCa at early stage is critical for disease prognosis and therapeutic intervention. One potential strategy for aggressive PCa is to target cancer stem cells (CSCs) that are identified by several unique characteristics such as immortal, self-renewal, and pluripotency. Also, CSC is believed to be a major factor contributing to resistance to radiotherapy and conventional chemotherapies. Moreover, CSCs are thought to be the critical cause of metastasis, tumor recurrence and cancer-related death of multiple cancer types, including PCa. In this review, we discuss recent progress made in understanding prostate cancer stem cells (PCSCs). We focus on the therapeutic strategies aimed at targeting specific surface markers of CSCs, the key signaling pathways in the maintenance of self-renewal capacity of CSCs, ATP-binding cassette (ABC) transporters that mediate the drug-resistance of CSCs, dysregulated microRNAs expression profiles in CSCs, and immunotherapeutic strategies developed against PCSCs surface markers.

Original languageEnglish (US)
Pages (from-to)203-210
Number of pages8
JournalAsian Journal of Urology
Volume3
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Neoplastic Stem Cells
Prostatic Neoplasms
Therapeutics
Neoplasms
Radiotherapy
Recurrence
ATP-Binding Cassette Transporters
Castration
MicroRNAs
Drug Resistance
Androgens
Neoplasm Metastasis
Drug Therapy

Keywords

  • Cancer stem cell
  • Normal stem cell
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

The evolving landscape of prostate cancer stem cell : Therapeutic implications and future challenges. / Yun, Eun Jin; Lo, U. Ging; Hsieh, Jer Tsong.

In: Asian Journal of Urology, Vol. 3, No. 4, 01.10.2016, p. 203-210.

Research output: Contribution to journalReview article

@article{9ca29e5ee5444c459efcfdfe2a58aa54,
title = "The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges",
abstract = "Prostate cancer (PCa) is the most common cause of malignancy in males and the second leading cause of cancer mortality in United States. Current treatments for PCa include surgery, radiotherapy, and androgen-deprivation therapy. Eventually, PCa relapses to an advanced castration-resistant PCa (CRPC) that becomes a systematic disease and incurable. Therefore, identifying cellular components and molecular mechanisms that drive aggressive PCa at early stage is critical for disease prognosis and therapeutic intervention. One potential strategy for aggressive PCa is to target cancer stem cells (CSCs) that are identified by several unique characteristics such as immortal, self-renewal, and pluripotency. Also, CSC is believed to be a major factor contributing to resistance to radiotherapy and conventional chemotherapies. Moreover, CSCs are thought to be the critical cause of metastasis, tumor recurrence and cancer-related death of multiple cancer types, including PCa. In this review, we discuss recent progress made in understanding prostate cancer stem cells (PCSCs). We focus on the therapeutic strategies aimed at targeting specific surface markers of CSCs, the key signaling pathways in the maintenance of self-renewal capacity of CSCs, ATP-binding cassette (ABC) transporters that mediate the drug-resistance of CSCs, dysregulated microRNAs expression profiles in CSCs, and immunotherapeutic strategies developed against PCSCs surface markers.",
keywords = "Cancer stem cell, Normal stem cell, Prostate cancer",
author = "Yun, {Eun Jin} and Lo, {U. Ging} and Hsieh, {Jer Tsong}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.ajur.2016.09.006",
language = "English (US)",
volume = "3",
pages = "203--210",
journal = "Asian Journal of Urology",
issn = "2214-3882",
publisher = "Elsevier (Singapore) Pte Ltd",
number = "4",

}

TY - JOUR

T1 - The evolving landscape of prostate cancer stem cell

T2 - Therapeutic implications and future challenges

AU - Yun, Eun Jin

AU - Lo, U. Ging

AU - Hsieh, Jer Tsong

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Prostate cancer (PCa) is the most common cause of malignancy in males and the second leading cause of cancer mortality in United States. Current treatments for PCa include surgery, radiotherapy, and androgen-deprivation therapy. Eventually, PCa relapses to an advanced castration-resistant PCa (CRPC) that becomes a systematic disease and incurable. Therefore, identifying cellular components and molecular mechanisms that drive aggressive PCa at early stage is critical for disease prognosis and therapeutic intervention. One potential strategy for aggressive PCa is to target cancer stem cells (CSCs) that are identified by several unique characteristics such as immortal, self-renewal, and pluripotency. Also, CSC is believed to be a major factor contributing to resistance to radiotherapy and conventional chemotherapies. Moreover, CSCs are thought to be the critical cause of metastasis, tumor recurrence and cancer-related death of multiple cancer types, including PCa. In this review, we discuss recent progress made in understanding prostate cancer stem cells (PCSCs). We focus on the therapeutic strategies aimed at targeting specific surface markers of CSCs, the key signaling pathways in the maintenance of self-renewal capacity of CSCs, ATP-binding cassette (ABC) transporters that mediate the drug-resistance of CSCs, dysregulated microRNAs expression profiles in CSCs, and immunotherapeutic strategies developed against PCSCs surface markers.

AB - Prostate cancer (PCa) is the most common cause of malignancy in males and the second leading cause of cancer mortality in United States. Current treatments for PCa include surgery, radiotherapy, and androgen-deprivation therapy. Eventually, PCa relapses to an advanced castration-resistant PCa (CRPC) that becomes a systematic disease and incurable. Therefore, identifying cellular components and molecular mechanisms that drive aggressive PCa at early stage is critical for disease prognosis and therapeutic intervention. One potential strategy for aggressive PCa is to target cancer stem cells (CSCs) that are identified by several unique characteristics such as immortal, self-renewal, and pluripotency. Also, CSC is believed to be a major factor contributing to resistance to radiotherapy and conventional chemotherapies. Moreover, CSCs are thought to be the critical cause of metastasis, tumor recurrence and cancer-related death of multiple cancer types, including PCa. In this review, we discuss recent progress made in understanding prostate cancer stem cells (PCSCs). We focus on the therapeutic strategies aimed at targeting specific surface markers of CSCs, the key signaling pathways in the maintenance of self-renewal capacity of CSCs, ATP-binding cassette (ABC) transporters that mediate the drug-resistance of CSCs, dysregulated microRNAs expression profiles in CSCs, and immunotherapeutic strategies developed against PCSCs surface markers.

KW - Cancer stem cell

KW - Normal stem cell

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85027837380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027837380&partnerID=8YFLogxK

U2 - 10.1016/j.ajur.2016.09.006

DO - 10.1016/j.ajur.2016.09.006

M3 - Review article

C2 - 29264188

AN - SCOPUS:85027837380

VL - 3

SP - 203

EP - 210

JO - Asian Journal of Urology

JF - Asian Journal of Urology

SN - 2214-3882

IS - 4

ER -